DNA

Amydis Announces Enrollment of First Participants in PROBE, a Phase 1/2a Trial Evaluating a Novel Retinal Tracer in People with Amyotrophic Lateral Sclerosis or Parkinson’s Disease

SAN DIEGO, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic…

2 years ago

Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand

Industry leading nerve repair surgeons will discuss data-driven best practices during symposium sessionALACHUA and TAMPA, Fla., Sept. 22, 2022 (GLOBE…

2 years ago

Akadeum Life Sciences Announces New Early Access Launch of First-of-its-Kind Microbubble-Powered, Large-Scale Cell Isolation Kit for Leukopaks

Akadeum’s microbubble technology allows scientists to effortlessly process up to twice as many leukopaks in as little as one-third the…

2 years ago

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted…

2 years ago

Predicine’s Liquid Biopsy Next-Generation Sequencing (NGS) Assay is Granted Breakthrough Device Designation by U.S. Food and Drug Administration

HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine…

2 years ago

Avricore Health Announces CEO Update Call on Sept. 22, 2022

VANCOUVER, British Columbia, Sept. 20, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is excited to…

2 years ago

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for…

2 years ago

Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering

HAYWARD, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or “the Company”), a development-stage, gene…

2 years ago

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15,…

2 years ago